Compares two PET imaging agents for finding prostate cancer in the same patients
Compares two PET scan tracers in adults newly diagnosed with prostate cancer.
Key facts
- Who runs it
- Peking Union Medical College Hospital
- Where
- Beijing, ChinaSee the site
- Trial code
- Registry title
- 68Ga-P16-093 and 68Ga-PSMA-11 PET/CT Imaging in the Same Group of Primary Prostate Cancer Patients
- Status
- Recruiting
- People taking part
- 50 people, planned
- Started
- 15 Apr 2022
- Planned end
- 31 Dec 2025
- Type of study
- Interventional
- Treatments tested
- 68Ga-P16-093
- 68Ga-PSMA-11
- Record updated
- 22 September 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for men with confirmed prostate cancer who have not been treated yet. Each man gets two PET/CT scans, with 68Ga-PSMA-11 and 68Ga-P16-093, within a week.
- Age
- 18 to 90 years
- Sex
- Men only
- Disease stage
- Primary prostate cancer, confirmed by tissue examination (histology)
- Earlier treatment
- No prior treatment for the prostate cancer
Main reasons for not taking part
- Known allergy against PSMA
- Any medical condition that, in the investigator's opinion, may significantly interfere with following the study
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- histologically confirmed untreated primary prostate cancer patients
- 68Ga-PSMA-11 and 68Ga-P16-093 PET/CT within a week
- signed written consent
Who cannot take part
- known allergy against PSMA
- any medical condition that in the opinion of the investigator may significantly interfere with study compliance
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 90 years old?
Where in China
- Peking Union Medical College HospitalBeijing, ChinaContact: Zhaohui Zhu, MDTaking people
About the trial
What the trial wants to find out
Prostate-specific membrane antigen (PSMA)-targeted PET imaging with 68Ga-labeled compounds is able to provide superior sensitivity and specificity to detect primary prostate tumor and its metastases, like the most widely studied 68Ga-PSMA-11. This pilot study was evaluate the diagnostic performance of 68Ga-P16-093, a novel radiopharmaceutical targeting PSMA, which was compared with 68Ga-PSMA-11 in the same group of primary prostate cancer patients.
The group in the trial
- 68Ga-P16-093 and 68Ga-PSMA-11 PET/ CT scanTreatment being tested
Patients of Prostate cancer PET/CT imaging: In two consecutive days, each patient underwent whole-body PET/CT scan after intravenous administration of 68Ga-P16-093 and 68Ga-PSMA-11, respectively.
Treatment: 68Ga-P16-093 and 68Ga-PSMA-11
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- A Pilot Comparison of 68Ga-P16-093 and 68Ga-PSMA-11 in the Same Group of Primary Prostate Cancer Patients
- Plain-language title
- Compares two PET imaging agents for finding prostate cancer in the same patientsGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT05324332, who can take part
- Publications
- [68Ga]Ga-P16-093 PET/CT in newly diagnosed prostate cancer: Histopathological validation and comparison with [68Ga]Ga-PSMA-11.European journal of nuclear medicine and molecular imaging, 2026
- Record updated
- 22 September 2025